News Feb 10, 2016
Stem cell-derived heart muscle cells may fail to effectively replace damaged cardiac tissue because they don't contract strongly enough. The possibility of using stem cells to replace damaged heart tissue following a heart attack has interested researchers for many years. Though stem cells transplanted into patients can develop into heart muscle cells (cardiomyocytes) and integrate with undamaged regions of cardiac tissue, several pre-clinical studies and clinical trials have failed to identify significant improvements in the contractile function of the heart.
One explanation for this could be that mechanical forces are not transmitted properly between the new, stem cell-derived cardiomyocytes and the old, surviving heart cells. The mechanical forces exchanged by cardiomyocytes are impossible to measure in patients. So, a team of researchers led by Professor Kit Parker at Harvard University developed a simplified, in vitro system in which single heart cells isolated from mice are combined with individual, stem cell-derived cardiomyocytes to form a two-cell "microtissue" that the researchers call a "muscle on-a-chip."
Using this approach, Pasqualini and Aratyn-Schaus, post-doctoral fellows in the Parker lab and co-first authors of the study, found that stem cell-derived cardiomyocytes could structurally couple, and synchronously beat with mouse cardiomyocytes. Stem cell-derived myocytes contracted less strongly than their partners, however, and this imbalance resulted in the cells transmitting mechanical forces to their surroundings, instead of to each other.
Computer simulations revealed that the unequal forces generated by stem cell-derived and native cardiomyocytes are sufficient to induce the formation of cellular adhesions that can dissipate force to the cells' surroundings. The computer model also suggests that human cardiomyocytes are likely to behave similarly.
Inefficient force transmission may therefore explain why stem cell transplantation has been somewhat ineffective in restoring normal heart function. Parker and colleagues' muscle on-a-chip technique should help researchers develop ways to improve the mechanical coupling of stem cell-derived cardiomyocytes to surviving heart tissue.
More than half of the drugs that have entered the market in Germany since then have emerged from these assessments without any proven added benefit. In a new publication using the first 216 assessments, researchers examine the reasons for this sobering result and develop suggestions for improvements in drug development.READ MORE